Elanix Biotechnologies AG (ELN-DE): Updates from webcast include financial outlook

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Elanix Biotechnologies AG (ELN-DE): Updates from webcast include financial outlook
Recommendation: OUTPERFORM
Target Price: EUR6.40
Current Price: EUR2.72 (cob on 7^th August 2018)

KEY TAKEAWAY

Elanix's management team hosted two webcasts today (one in German, one in English) aimed at enhancing transparency and increasing communication with current and potential future shareholders. Key updates included: (1) Ongoing commercialisation activities for marketed product GYNrepair (first launched in May 2017), (2) timeline for additional launches from the advanced skin care ("ASC") segment, including SKINrepair in Q4/2018, (3) financial outlook to 2022, and (4) a formal introduction by new COO & CFO Egon Minar. Apart from a small delay to the launch of SKINrepair and a therefore slightly lower target for 2018 revenues than we currently model, Elanix is on track vs. our expectations. We remain enthusiastic about the commercial outlook of Elanix's ASC and advanced wound care ("AWC") assets, based on their differentiated profiles, large target markets and unmet medical needs. Hence, we maintain and reiterate both our OUTPERFORM recommendation and target price of EUR6.40 per share.

Commercial roll-out of GYNrepair on track; e-commerce playing a central role

Management reiterated that the commercialisation strategy for GYNrepair focuses on three channels: pharmacies, direct marketing to KOLs (gynaecologists and dermatologists), and e-commerce. The latter has been the most successful, accounting for c.50% of sales in July. The direct approach targeting pharmacies is also on track: Elanix has already signed three distributors in Benelux, Switzerland and Russia, and is in negotiations with 50 large accounts mainly in Germany, France and Switzerland, but also UK, Italy and Spain. Management expects to get more traction once SKINrepair reaches the market for skin irritations later this year and has also approached distribution partners in the US and Japan. This includes a potential partnership with an undisclosed US company, which could bring the launch of SKINrepair in the US forward to mid-2019 (our forecasts currently assume 2020E).

SKINrepair to be launched in October, four additional ASC creams by 2020

Limited financial resources slightly delayed the launch of SKINrepair to October (originally planned for H1/2018). Elanix intends to launch two additional ASC products in each 2019 and 2020, bringing the total on the market to six by end 2020. This could lead to upside vs. our current forecasts, which only include GYNrepair and SKINrepair. Revenues from the additional ASC assets, which include gels, masks and creams, will be used to advance the AWC portfolio.

Financial outlook provided for the first time anticipates break-even in 2020

Management expects to achieve sustainable profitability in 2020 and reach revenues of c.EUR33.5m in 2022, broadly in line with our forecasts. This is based on prudent cost management in line with the ability to raise the necessary funds, both from the ongoing rights issue, which aims to raise EUR2.1m, as well as from additional, potentially non-dilutive sources. The current capital injection is anticipated to take the company through to early 2019, indicating further financing will be required in the coming six months.

New COO & CFO brings wealth of commercial experience to the table

Elanix appointed Egon Minar, who has a predominantly commercial background, to the combined position of COO & CFO in May. Upon successful completion of the ongoing capital increase, Elanix intends to appoint a finance director who would take over the CFO role in due course to allow Egon Minar to fully focus on operational matters as well as investor relations, which management recognises requires additional resources.

Kind regards,

Brigitte de Lima, PhD, CFA | Analyst
Martin Piehlmeier | Analyst
goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | healthcareresearch@goetzpartners.com / brigitte.delima@goetzpartners.com / martin.piehlmeier@goetzpartners.com

www.goetzpartnerssecurities.com

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

Click here to see our privacy policy.

GPSL has a formal client relationship with Elanix Biotechnologies AG.

GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation ("GDPR") - if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This e-mail (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, Research Tree, RNS Reach and Thomson Reuters.

If you cannot click on the above hyperlink please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=ca7ae89a-e144-4c84-bf21-b46a69e4e1d9&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.